封面
市场调查报告书
商品编码
1760989

全球核医放射性同位素市场

Nuclear Medicine Radioisotope

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年,全球核医放射性同位素市场规模将达到 166 亿美元

全球核医放射性同位素市场规模预计在2024年为106亿美元,到2030年将达到166亿美元,在2024-2030年的分析期间内,复合年增长率为7.8%。Technetium-99m(Tc-99m)是本报告分析的细分市场之一,预计其复合年增长率为8.7%,到分析期结束时将达到117亿美元。铊-201(Tl-201)细分市场在分析期间的复合年增长率预计为6.2%。

美国市场规模估计为 30 亿美元,中国市场预期复合年增长率为 7.1%

美国核医放射性同位素市场规模预计2024年达到30亿美元。作为世界第二大经济体,中国预计到2030年市场规模将达到25亿美元,在2024-2030年的分析期间内,复合年增长率为7.1%。其他值得关注的区域市场包括日本和加拿大,预计在分析期间内,这两个市场的复合年增长率分别为7.4%和6.2%。在欧洲,预计德国市场的复合年增长率约为6.2%。

全球核医学放射性同位素市场—主要趋势与驱动因素摘要

什么是核医放射性同位素?为什么它们很重要?

核子医学放射性同位素是用于诊断影像和治疗的放射性物质,主要用于肿瘤学、心臟病学和神经病学领域。这些同位素会发出辐射,使医生能够拍摄器官、组织和骨骼的详细影像,有助于检测癌症、心臟病和阿兹海默症症等疾病。常见的放射性同位素包括用于诊断成像的Technetium-99m(Tc-99m)和用于治疗甲状腺癌的碘-131。放射性同位素在核子医学中发挥重要作用,因为它们可以实现PET和SPECT扫描等非侵入性成像技术,因此无需手术即可提供高度准确的诊断。放射性药物等治疗应用可以进行标靶治疗,最大限度地减少对健康组织的损害,从而改善患者的预后。

技术创新如何影响核医放射性同位素市场?

放射性药物和同位素生产技术的进步正在显着影响核医放射性同位素市场。先进迴旋加速器和核子反应炉的发展提高了放射性同位素生产的效率和安全性。此外,随着医疗保健系统寻求降低与核子反应炉相关的风险并确保稳定的供应,对替代生产方法的研究也日益增多,例如无需核子反应炉即可生产Technetium-99m。放射性药物配方的进步也使得放射性同位素的标靶性更加精准,从而提高了诊断的准确性和治疗效果。此外,人工智慧 (AI) 正被应用于核医学,以改善影像分析,使临床医生能够更快、更准确地做出诊断。

疾病模式和消费行为的改变如何影响对放射性同位素的需求?

慢性病,尤其是癌症和心血管疾病的盛行率不断上升,推动了全球对核医放射性同位素的需求。随着全球癌症诊断率的上升,放射性同位素在早期发现和标靶治疗中发挥关键作用。随着患者和医疗保健提供者越来越重视非侵入性诊断工具和个人化治疗计划,消费行为也正在影响市场。在先进医疗技术更容易获得的地区,核医学正在被纳入标准医疗保健实践。此外,世界人口老化推动了对核子医学在诊断和治疗与老龄化相关的疾病(如失智症和退化性心臟疾病)方面的需求。随着患者对核医学认识的提高,对高品质、快速诊断解决方案的需求也增加。

核医学放射性同位素市场的成长受多种因素驱动

核医学放射性同位素市场的成长受到多种因素的推动,包括技术进步、医疗保健需求的不断增长以及放射性药物的日益普及。迴旋加速器技术和放射性药物的创新提高了放射性同位素的安全性、准确性和可用性,从而扩大了其在医学影像和癌症治疗中的应用。癌症和心血管疾病等慢性疾病的流行是诊断影像和治疗应用的主要驱动力,从而推动了对Technetium-99m和碘-131等特定同位素的需求。此外,个人化医疗的转变正在扩大标靶放射性同位素治疗的应用,这种治疗方案疗效更佳,副作用更少。政府(尤其是在新兴市场)支持核医基础设施的倡议,以及医院PET和SPECT扫描仪的日益普及,也对市场发展做出了重大贡献。最后,供应链的改进,包括非反应器同位素生产方法的开发,正在使医用同位素更加可靠和永续性,从而进一步刺激市场扩张。

部分

放射性同位素类型(Technetium-99m(Tc-99m)、铊-201(Tl-201)、镓-67(Ga-67)、碘(I-123)、其他类型的放射性同位素);用途(心臟病学、肿瘤学、神经病学、淋巴瘤、甲状腺、其他用途)

受访公司范例(42家值得关注的公司)

  • Bayer Healthcare AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • GE Healthcare
  • Hologic, Inc.
  • Lantheus Medical Imaging, Inc.
  • Medtronic PLC
  • NTP Radioisotopes SOC Ltd.
  • Positron Corporation
  • Siemens Healthineers

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 并未遵循查询 LLM 或特定产业SLM 的典型规范,而是建立了一个来自全球领域专家的精选内容库,其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况(成品和原始OEM)预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手,包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP13634

Global Nuclear Medicine Radioisotope Market to Reach US$16.6 Billion by 2030

The global market for Nuclear Medicine Radioisotope estimated at US$10.6 Billion in the year 2024, is expected to reach US$16.6 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Technetium-99m (Tc-99m), one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$11.7 Billion by the end of the analysis period. Growth in the Thallium-201 (Tl-201) segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 7.1% CAGR

The Nuclear Medicine Radioisotope market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Nuclear Medicine Radioisotope Market - Key Trends & Drivers Summarized

What Are Nuclear Medicine Radioisotopes and Why Are They Important?

Nuclear medicine radioisotopes are radioactive substances used in diagnostic imaging and therapeutic treatments, primarily in the field of oncology, cardiology, and neurology. These isotopes emit radiation that allows doctors to capture detailed images of organs, tissues, and bones, aiding in the detection of diseases such as cancer, heart disease, and Alzheimer’s. Common radioisotopes include Technetium-99m (Tc-99m) for diagnostic imaging and Iodine-131 for treating thyroid cancer. Radioisotopes play a critical role in nuclear medicine because they enable non-invasive imaging techniques, such as PET and SPECT scans, providing high-precision diagnostics without the need for surgery. Their therapeutic applications, such as radiopharmaceuticals, allow for targeted treatments that minimize damage to healthy tissue, enhancing patient outcomes.

How Are Technological Innovations Shaping the Nuclear Medicine Radioisotope Market?

Technological advancements in radiopharmacy and isotope production are significantly shaping the nuclear medicine radioisotope market. The development of advanced cyclotrons and nuclear reactors has improved the efficiency and safety of radioisotope production. Additionally, research into alternative production methods, such as non-reactor-based generation of Technetium-99m, is gaining momentum as healthcare systems seek to mitigate the risks associated with nuclear reactors and ensure a stable supply. Advancements in radiopharmaceutical formulations have also allowed for more precise targeting of radioisotopes, enhancing both the diagnostic accuracy and therapeutic efficacy of treatments. Furthermore, artificial intelligence (AI) is being integrated into nuclear medicine to improve image analysis, allowing clinicians to make faster and more accurate diagnoses.

How Are Changing Disease Patterns and Consumer Behavior Impacting Demand for Radioisotopes?

The increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, is driving global demand for nuclear medicine radioisotopes. With cancer diagnoses rising worldwide, radioisotopes are playing a critical role in both early detection and targeted therapies. Consumer behavior is also influencing the market, as patients and healthcare providers increasingly prioritize non-invasive diagnostic tools and personalized treatment plans. In regions where access to advanced medical technologies is expanding, nuclear medicine is becoming more integrated into standard healthcare practices. Additionally, an aging global population is creating greater demand for nuclear medicine in the diagnosis and treatment of age-related diseases, such as dementia and degenerative heart conditions. As patient awareness of nuclear medicine grows, so does the demand for high-quality, fast-acting diagnostic solutions.

Growth in the Nuclear Medicine Radioisotope Market Is Driven by Several Factors

The growth in the nuclear medicine radioisotope market is driven by several factors, including technological advancements, evolving healthcare needs, and the increasing adoption of radiopharmaceuticals. Innovations in cyclotron technology and radiopharmaceuticals are improving the safety, precision, and availability of radioisotopes, which is encouraging wider use in medical imaging and cancer therapies. The growing prevalence of chronic diseases, such as cancer and cardiovascular disorders, is a major driver for diagnostic imaging and therapeutic applications, pushing demand for specific isotopes like Technetium-99m and Iodine-131. Additionally, the shift toward personalized medicine is expanding the use of targeted radioisotope therapies, which offer more effective treatment outcomes with fewer side effects. Government initiatives supporting nuclear medicine infrastructure, particularly in developing regions, and the increasing availability of PET and SPECT scanning devices in hospitals are also significant contributors to market growth. Finally, supply chain improvements, including the development of non-reactor-based isotope production methods, are ensuring a more reliable and sustainable supply of medical isotopes, further fueling the market’s expansion.

SCOPE OF STUDY:

The report analyzes the Nuclear Medicine Radioisotope market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Radioisotope Type (Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123), Other Radioisotope Types); Application (Cardiology, Oncology, Neurology, Lymphoma, Thyroid, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Bayer Healthcare AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • GE Healthcare
  • Hologic, Inc.
  • Lantheus Medical Imaging, Inc.
  • Medtronic PLC
  • NTP Radioisotopes SOC Ltd.
  • Positron Corporation
  • Siemens Healthineers

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Nuclear Medicine Radioisotope - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Prevalence of Cancer and Cardiovascular Diseases Spurs Strong Growth in the Nuclear Medicine Radioisotope Market
    • Technological Innovations in Radiopharmaceuticals Expand the Addressable Market Opportunity for Nuclear Medicine Radioisotopes
    • Aging Population and Rising Life Expectancy Worldwide Strengthen the Business Case for Greater Utilization of Radioisotopes in Healthcare
    • Expansion of PET-CT and SPECT Imaging Technology Propels Growth in Diagnostic Applications for Nuclear Medicine
    • Government Healthcare Initiatives and Infrastructure Modernization Projects Drive the Adoption of Nuclear Medicine Radioisotopes
    • Rising Demand for Minimally Invasive Diagnostic and Therapeutic Techniques Generates New Opportunities for Radioisotope-Based Solutions
    • Continuous Advancements in Cyclotron and Reactor Technologies Sustain Long-Term Growth in Global Radioisotope Production
    • Development of Targeted Radiotherapy Expands the Scope and Effectiveness of Therapeutic Nuclear Medicine Radioisotopes
    • Increased Focus on Precision Medicine and Personalized Treatments Strengthens Demand for Nuclear Medicine Radioisotopes in Oncology
    • Rising Incidence of Neurological and Neurodegenerative Disorders Accelerates Demand for Diagnostic Radioisotopes in Brain Imaging
    • Stringent Regulatory Approvals, Safety Protocols, and Licensing Challenges Present Barriers to Market Growth for Nuclear Medicine Radioisotopes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nuclear Medicine Radioisotope Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nuclear Medicine Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Nuclear Medicine Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Technetium-99m (Tc-99m) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Technetium-99m (Tc-99m) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Technetium-99m (Tc-99m) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Thallium-201 (Tl-201) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Thallium-201 (Tl-201) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Thallium-201 (Tl-201) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Gallium-67 (Ga-67) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Gallium-67 (Ga-67) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Gallium-67 (Ga-67) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Iodine (I-123) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Iodine (I-123) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Iodine (I-123) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Radioisotope Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Thyroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Thyroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Thyroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Nuclear Medicine Radioisotope by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Nuclear Medicine Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Nuclear Medicine Radioisotope Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Nuclear Medicine Radioisotope by Radioisotope Type - Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of World 15-Year Perspective for Nuclear Medicine Radioisotope by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Gallium-67 (Ga-67), Iodine (I-123) and Other Radioisotope Types for the Years 2015, 2025 & 2030
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of World Historic Review for Nuclear Medicine Radioisotope by Application - Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of World 15-Year Perspective for Nuclear Medicine Radioisotope by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology, Lymphoma, Thyroid and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION